| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase subunit p85-alpha; PtdIns-3-kinase regulatory subunit p85-alpha |
| Entrez GeneID | 5295 |
| clone | 1C8 |
| WB Predicted band size | Calculated MW: 84 kDa; Observed MW: 84 kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Purified recombinant protein expressed in E.coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于PI3 Kinase p85 alpha抗体的3篇参考文献，简要概括内容：
1. **"Phosphatidylinositol 3-kinase: Structure and expression of the p85 alpha subunit"**
- 作者：Carpenter CL, et al.
- 摘要：该研究通过制备特异性p85 alpha抗体，分析了其在哺乳动物细胞中的表达及与p110催化亚基的相互作用，验证了抗体在免疫沉淀和Western blot中的应用。
2. **"Characterization of phosphoinositide 3-kinase p85α/p55α isoforms in immune signaling"**
- 作者：Fruman DA, et al.
- 摘要：利用p85 alpha特异性抗体研究其在免疫细胞中的功能，揭示了其在调控B细胞受体信号中的关键作用，并验证了抗体检测磷酸化修饰的可靠性。
3. **"Role of p85α in hepatic insulin signaling and glucose homeostasis"**
- 作者：Hara K, et al.
- 摘要：通过敲除小鼠模型结合p85 alpha抗体的免疫组化分析，发现该亚基在肝脏胰岛素信号通路中负向调节葡萄糖代谢，抗体用于定位组织中的蛋白分布。
4. **"Regulation of PI3K signaling in cancer and metabolic disease"**
- 作者：Ueki K, et al.
- 摘要：综述中总结了p85 alpha抗体在检测肿瘤和代谢疾病中PI3K通路异常的应用，包括检测突变导致的蛋白稳定性变化及其临床相关性。
以上文献均涉及p85 alpha抗体的实验应用，涵盖蛋白互作、信号机制及疾病模型研究。
The PI3 kinase p85 alpha antibody is a crucial tool for studying the phosphoinositide 3-kinase (PI3K) signaling pathway, which regulates cell growth, survival, metabolism, and apoptosis. PI3K consists of a regulatory subunit (p85) and a catalytic subunit (p110). The p85 alpha isoform (encoded by *PIK3R1*) stabilizes p110. modulates PI3K activity, and acts as an adaptor protein linking receptor tyrosine kinases to downstream signaling. It also exhibits kinase-independent tumor-suppressive roles by interacting with proteins like PTEN or RAS.
Antibodies targeting p85 alpha are used to detect its expression, phosphorylation status, subcellular localization, and protein interactions via techniques like Western blotting, immunohistochemistry (IHC), immunoprecipitation (IP), or immunofluorescence (IF). These antibodies help explore PI3K pathway dysregulation in cancers, diabetes, and immune disorders. For instance, p85 alpha mutations or altered expression are linked to glioblastoma, breast cancer, and insulin resistance.
Most commercial p85 alpha antibodies are monoclonal or polyclonal, raised against specific epitopes (e.g., N-terminal SH3 or C-terminal SH2 domains). Species reactivity typically includes human, mouse, and rat. Validation often involves knockout (KO) cell lines or siRNA-mediated silencing to confirm specificity. Researchers rely on these antibodies to investigate therapeutic targets, as PI3K inhibitors are in clinical trials for oncology and inflammatory diseases. Proper antibody selection is critical, as cross-reactivity with other p85 isoforms (beta, gamma) may occur depending on epitope regions.
×
